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Abstract
Summary In this population-based, cross-sectional study
in Italian postmenopausal females not affected by dia-
betes, we showed a link between serum C-peptide and
lumbar bone mineral density, suggesting that C-peptide
exerts an insulin-independent effect on bone mass.
Introduction It is well known that type 1 (T1) diabetes,
characterized by insulin and C-peptide deficiency, is as-
sociated with a low lumbar bone mineral density and an
increased risk for fracture. While a role for insulin in
the pathogenesis of osteoporosis has been demonstrated,
the association between C-peptide and the bone mineral
density has not been investigated. We conducted a study
in a cohort of 84 postmenopausal women without dia-
betes to clarify the association between serum C-peptide
and the lumbar bone mineral density.
Methods Participants underwent a bone mineral density eval-
uation by DXA and biochemical analysis including the C-
peptide assay.
Results rteen percent of the population had osteoporosis and
38% had osteopenia.With ANOVA test, we showed that wom-
en with the lowest C-peptide concentration had lower lumbar
mineral density in comparison to those in all other C-peptide
concentration group (p=0.02 among groups after adjustment).
The univariate and multivariate analysis showed that C-peptide
was positively associated with both lumbar T-score and Z-score
besides other well-known factors like age (with T-score
p<0.001; beta=−0.38) and BMI (with T-score p=0.009; be-
ta=0.34), while insulin was not correlated with the lumbar bone
mineral density. The area under the receiver operating charac-
teristic (ROC) curve for C-peptide to predict the absence of
lumbar osteoporosis was 0.74 (SE=0.073; p=0.013).
Conclusions These results suggest that C-peptide may exert
an insulin- and BMI-independent effect on lumbar bone min-
eral density and that further large-scale studies are needed in
order to clarify its role in bone mineralization especially in
subjects without diabetes.
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Introduction
Several studies have shown opposite results for type 1 (T1D)
and type 2 diabetes (T2D) concerning the appearance of oste-
oporosis. In fact, it has been shown that a declined bone min-
eral density (BMD) associated with an increase in fracture risk
in T1D [1–3] while an unpredictable BMD change and a var-
iable fracture risk have been reported in T2D [2, 4].
In particular, it has been shown that the lumbar bone min-
eral density (LBMD) is lower in adolescents and adults with
T1D compared to control population [5–7].
Insulin is crucial in osteoblast differentiation from marrow
stromal cells [8]; thus, its role in the pathogenesis of osteopo-
rosis in diabetes has been proposed [9]. However, insulin and
C-peptide are secreted in equimolar concentrations from the
pancreas. Since C-peptide has irrelevant extraction by the liv-
er, constant peripheral clearance and its half-life is longer than
insulin [10–12], it is commonly used in preference to insulin
assessment. In addition, C-peptide has a central function in the
synthesis and correct folding of insulin; therefore, a role also
for C-peptide may be hypothesized in osteoporosis. Recent
studies have demonstrated specific binding of C-peptide to
cell surfaces(to pancreatic islets and red blood cells of rat
and to cultured human renal tubular cells, fibroblasts, and
endothelial cells) with the subsequent stimulation of specific
intracellular processes involving Na+-K+-ATPase activity, a
key mechanism for bone mineralization [13, 14]. This finding
may explain the positive correlation between both LBMD and
femoral bone mineral density (FBMD) with C-peptide in pa-
tients with T1D [15]. However, a recent investigation has
shown that serum C-peptide was negatively associated with
BMD in individuals without diabetes and that this association
was independent of the serum insulin levels and dependent of
age [16]. Thus, at this moment, the definitive link between C-
peptide and BMD is not yet clarified and needs to be investi-
gated. Consequently, we conducted a study in a cohort of
postmenopausal women without diabetes to clarify the even-
tual association between serum C-peptide and both LBMD
and FBMD. Furthermore, we examined whether other factors
such parathyroid hormone (PTH), 25-OH vitamin D (the most
important regulators of calcium homeostasis), and the fibro-
blast growth factor 23 (FGF-23) (the main phosphate-
regulating hormone) [17] were affecting this association.
Methods
This survey is in progress since 2011 in the regions of Lom-
bardia and Calabria, Italy, and involves white postmenopausal
female volunteers aged more than 45 years, invited by news-
papers ads to participate in the study and consecutively en-
rolled. The subjects of this investigation consisted of the first
84 postmenopausal women without diabetes, who completed
all the examinations at May 2014.
All participants underwent a brief interview to provide in-
formation about familiarity for osteoporosis, current physical
exercise activity as the usual daily time spent outside walking
(more than 30 min) [18], smoke habits, medications use, and
history of fractures. Pathological or high-energy fractures and
fractures in sites not commonly associated with osteoporosis
were not considered in the statistical analysis. Postmenopausal
status was defined as the presence of a serum follicle-
stimulating hormone (FSH) level of over 40 IU/l (if available)
or no natural menses for at least 1 year.
Subjects were excluded if they had self-report diagnosis of
T1D or T2D and/or they were taking antidiabetic medication
and/or insulin or they had fasting plasma glucose concentra-
tion equal or more than 126 mg/dl, or any clinical condition
that affects bone metabolism, such as diseases of the kidney,
liver, thyroid, or parathyroids, rheumatic diseases, malabsorp-
tion syndromes, malignant tumors, and hematological dis-
eases. None were taking drugs or hormones that influence
bone metabolism, such as glucocorticoids, estrogens, thyroid
hormone, fluoride, bisphosphonate, calcitonin, thiazide di-
uretics, barbiturates, vitamin D, or calcium-containing drugs.
All participants underwent both the LBMD and FBMD as-
sessment, and a blood sample was collected for the biochem-
ical analysis. We obtained their informed consent to partici-
pate in the study. The study was approved by both the Ethic
Committee ASL Milan 2 and the University Hospital Mater
Domini, Catanzaro. The investigation conforms to the princi-
ples outlined in the Declaration of Helsinki.
DXA assessment
Postmenopausal women underwent a BMD evaluation of the
lumbar spine and left femur byDXA (Hologic QDR Inc., MA,
USA, 17). BMD was expressed as the amount of mineral (g)
divided by the area scanned (cm2). Bone density was then
expressed as the T-score, calculated on the basis of the normal
reference values. The T-score is defined as the number of
standard deviations from the healthy young adult mean (nor-
mal, > −1; osteopenia, −1 to −2.49; osteoporosis, ≤ −2.5)
while the Z-score was the number of standard deviations in
comparison to healthy women of the same age [19, 20]. The
instrument was calibrated every day in accordance with the
manufacturer’s recommendations. The in vivo precision was
established on the basis of repeated measurements in 30 wom-
en and was <1 %.
Nutritional calcium intake and anthropometric measurements
The participant’s nutritional calcium intake was calculated
using the nutritional software MetaDieta 3.0.1 (MeTeDa srl,
S. Benedetto del Tronto, Italy) [21] and categorized into two
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groups (normal intake-low intake). Body weight was mea-
sured before breakfast with the subjects lightly dressed,
subtracting the weight of clothes. Body weight was measured
with a calibrated scale and height measured with a wall-
mounted stadiometer. BMI was calculated with the following
equation: weight (kg) / (height (m))2
Biochemical evaluation
Venous blood was collected after fasting overnight into
Vacutainer tubes (Becton & Dickinson) and centrifuged with-
in 2 h. Serum glucose, phosphate, and hemoglobin A1c
(HbA1c) were measured by standard laboratory techniques
(enzymatic colorimetric test) [22]. Serum calcium (reference
values (r.v.) 8.9–10.1 mg/dL) was evaluated with a colorimetric
assay according to Schwarzenbach, using o-cresolphthalein-
complexone [23]. Serum insulin was assessed with
cheminumilescent microparticle immunoassay (CMIA) (ARCH
ITECT insulin assay Abbott Laboratories, assay precision of
≤7 % total coefficient variation (CV)). Standard C-peptide
assay was performed with CMIA (ARCHITECT C-peptide
assay Abbott, Germany; assay precision of ≤10 % total CV).
Concentrations of soluble FGF-23 (r.v. 10–50 pg/ml) and
N-terminal telopeptide (NTx) (r.v. 19–63 nM BCE/nM
creatinine) in serum were determined by commercial ELISA
assay (Human FGF-23 (C-term) ELISA Kit, San Clemente,
CA, USA; Osteomark NTx serum ELISA, Wampole
Laboratories, Princeton, NJ, USA). The intact PTH
(r.v. 15–65 pg/mL) and 25-hydroxyvitamin D [(25OH)D] (r.v.
30.0–100.0 ng/mL) were measured by radioimmunoassay [24].
Internal quality control (IQC) was performed every day for all
determination.
Statistical analysis
Data are reported as mean±standard deviation (SD). Eighty-
five subjects are required to detect a correlation between C-
peptide and LBMD and FBMD equal to 0.30, considered to be
clinically meaningful, with 80 % power on a two-sided level
of significance of 0.05.
A chi-square test was performed to analyze the difference
of the prevalence between groups. The ANOVAwas used to
compare the means between groups (on the basis of C-peptide
concentration tertiles) with Sheffe’s post hoc test. Pearson
correlation was used to identify the variables correlated to
both the LBMD and FBMD expressed as T-score and Z-
score (the number of SDs) given that the continuous variables
were normally distributed. Non-normally distributed data
were log transformed. The multivariate linear stepwise regres-
sion analysis was used to test the association between C-
peptide and BMD adjusting for confounding variables select-
ed from univariate analysis having a p<0.1 (in model I), con-
sidering LBMD and FBMD (as T-score or Z-score) as
dependent variables, in the separate analysis. In model II, in
the multivariate linear stepwise regression analysis, we includ-
ed also the log-transformed insulin. In model III, in the mul-
tivariate linear stepwise regression analysis we included,
among confounding variables, also smoking, physical exer-
cise, and familiarity for osteoporosis. The general linear model
(GLM)was used to adjust LBMD (T-score value) for BMI and
glucose. Furthermore, the area under the receiver operating
characteristic (ROC) curve was used to analyze the capacity
of C-peptide to predict the absence of osteoporosis at lumbar
spine. Significant differences were assumed to be present at
p<0.05 (two-tailed). All comparisons were performed using
SPSS 20.0 for Windows (S. Wacker Drive, Chicago, IL
60606, USA).
Results
The mean age of the population was 56±6 years. A
total of 12 subjects (14 %) had osteoporosis, 32
(38 %) had osteopenia, and 40 (48 %) had a normal
BMD. Hypovitaminosis D was present in 18, 40, and
42 % and familiarity for osteoporosis in 7, 13, and
50 % of normal, osteopenic, and osteoporotic subjects,
respectively. Only one subject did not complete all the
examinations. Table 1 shows the characteristics of the
study population. At univariate (Table 2, showing only
factors significantly correlated to BMD) and multivariate
Table 1 Characteristics of whole non-diabetic population (N=84)
Variables Mean SD
Age (years) 53 6
Weight (Kg) 66.0 14
Height (cm) 161 7
BMI (kg/m2) 25 5
Lumbar T-score −0.94 1
Lumbar Z-score 0.03 1
Femur Neck T-score −1.13 1
Femur neck Z-score −0.25 1
Phosphorus (mg/dL) 3.6 0.4
Calcium (mg/dL) 9.4 0,4
Glucose (mg/dL) 91.2 9
Insulin (μU/mL) 8.4 4
C-peptide (ng/mL) 1.82 0.7
HbA1c (%) 5.6 0.2
PTH (pg/mL) 45.27 19
Vitamin D (ng/mL) 26.4 10
NTx (nM BCE/nM creatinine) 27.6 7
FGF-23 (pg/mL) 9.2 6
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(Table 3) analysis, after adjusting for confounding fac-
tors, there was no association between C-peptide and
FBMD (both T-score, see Table 3, and Z-score, not
showed), while C-peptide was associated with LBMD
(with both T-score and Z-score, see Table 3) as well
as age and BMI (with T-score: C-peptide p=0.01, be-
ta=0.33; age p<0.001, beta=−0.38; BMI p=0.009, be-
ta=0.34; variance inflation factor—VIF=1.91, 1.00, 1.92
for C-peptide, age, and BMI, respectively; tolerance=
0.52, 0.99, 0.52 for C-peptide, age, and BMI, respec-
tively. Model I, Table 3). Interestingly, log-transformed
insulin was not correlated with LBMD (with T-score:
p=0.66; beta 0.072; t=0.43, ,model II). In the multivar-
iate analysis, the correlation between LBMD (measured
by T-score) and glucose disappeared (models I, II, and
III of Table 3, see legend). In addition, PTH, FGF-23,
and 25-OH vitamin D were not correlated (Table 2).
Since BMI result correlated to C-peptide (r=0.63,
p<0.001), we performed a multivariate analysis with
C-peptide corrected for BMI and the correlation did
not change. To confirm all these associations, we cate-
gorized the population according to C-peptide tertiles. In
Table 4, the prevalence of the risk factors for osteopo-
rosis according to C-peptide tertiles is showed. Conse-
quently, in the multivariate analysis, we further adjusted
the data for smoke, physical exercise, and familiarity
(Table 4) but these factors did not affect the associa-
tions (model III in Table 3, see legend, data not
showed).
Table 5 shows the characteristic of the population
according to C-peptide concentration tertiles. Analysis
by ANOVA revealed that women with the lowest C-
peptide concentration (tertile I) had lower average
LBMD (both T-score and Z-score) in comparison to
those in all other tertiles (p=0.03 among tertiles; tertile
I vs tertile III p<0.001; tertile II vs tertile III p=0.019,
respectively; Table 5 and Fig. 1). Because of the signif-
icant difference in the BMI and glucose among C-
peptide tertiles (Table 5), a GLM was performed to
adjust LBMD (T-score value) for these factors,
confirming the lower LBMD in those with the lowest
C-peptide (p=0.02 after adjustment, Table 5). The area
under the ROC curve for C-peptide to predict the ab-
sence of lumbar osteoporosis was 0.74 (SE=0.073; p=
0.013). The C-peptide equal to 1.31 achieved satisfacto-
ry sensitivity (75 %) and specificity (60 %) (Fig. 2).
Table 2 Univariate analysis—
Pearson correlation Variables Age BMI Insulin C-peptide Calcium Vitamin D Glucose
LBMD
(Z-score)
r – 0.53 0.50 0.51 – – 0.25
p – <0.001 <0.001 <0.001 – – 0.01
LBMD
(T-score)
r −0.3 0.48 0.47 0.48 −0.19 – 0.20
p 0.001 <0−001 <0.001 <0.001 0.07 – 0.05
FBMD
(T-score)
r −0.37 0.47 0.38 0.34 −0.19 −0.23 –
p <0.001 <0.001 0.001 0.001 0.07 0.03 –
Table 3 Multivariate linear regression analysis—factors correlated to














Age −0.08 −0.38 −4.2 <0.001
BMI 0.08 0.34 2.6 0.009
C-peptide 0.60 0.33 2.5 0.01
LBMD
Z-scoreb
BMI 0.08 0.34 2.8 0.005
C-peptide 0.50 0.29 2.4 0.01
FBMD
T-scorec
Age −0.06 −0.39 −4.5 <0.001
BMI 0.10 0.48 5.5 <0.001
a Excluded variables—model I: calcium, glucose; model II: calcium, log
insulin, glucose; model III: calcium, log insulin, glucose, smoke, physical
exercise, familiarity
b Excluded variables—model I: log insulin, glucose; model II: log insulin,
glucose, smoke, physical exercise, familiarity
c Excluded variables—model I: calcium, log insulin, vitamin D,
C-peptide; model II: calcium, log insulin, vitamin D, C-peptide, smoke,
physical exercise, familiarity











Current smokers (%) 32 21 7 0.03 vs no smokers
Normal calcium intake (%) 67 60 71 0.33 vs low
calcium intake
Exercise habitually(%) 53 46 28 0.02 vs no exercise




17 10 0 0.05 vs no familiar
history
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Discussion
The results of this population-based, cross-sectional study in
Italian postmenopausal females not affected by diabetes
showed that serum C-peptide was strongly associated with
LBMD (with both T-score and Z-score value) (Table 2) also
after adjustment for several factors (Table 3). In addition, the
main calcium-phosphate regulating hormones (PTH, 25-OH
vitamin D, and the FGF-23) did not affect this association that
was also independent of the serum insulin. We also found that
postmenopausal women in the lowest serum C-peptide con-
centration tertile had the lower LBMD in comparison to those
in the highest C-peptide tertiles (Table 5). With these results,
we infer that a low C-peptide concentration could be a novel
osteopenic marker in postmenopausal women not affected by
diabetes, if confirmed.
It is well known that T1D, that is characterized by an insu-
lin and C-peptide deficiency, is associated with a low LBMD
and an increased risk for fracture [1, 2, 5–7]. A role for insulin
in osteoblastogenesis has been proposed [25]. Furthermore,
recent investigations have suggested that C-peptide is not bi-
ologically inert but that it is a separate entity with different
characteristics from those of insulin [13]. It has been shown
that C-peptide involves the activation of Ca2+-dependent sig-
naling pathways with consequent stimulation of Na+-K+-
ATPase [13] via specific binding as a ligand to its receptor.
The transfer of inorganic phosphate into osteoblastic cells,
important in bone formation, is related to the transmembrane
electrochemical gradient of sodium maintained by Na,K-
ATPase [14]. In addition, bone mineralization critically de-
pends upon optimal calcium homeostasis in osteoblasts. To
establish optimal intracellular [Ca2+], osteoblasts need Ca-
ATPase and Na/Ca exchange systems whose activities depend
on the activity of Na,K-ATPase [26]. Thus, C-peptide may be
not only a marker but it may also have an active role in the
development of osteoporosis. However, whether C-peptide
acts also in concert with insulin remains to be elucidated. In
this contest, it is important reflect also on the role of the islet
amyloid pancreatic polypeptide (IAPP, amylin) that is a hor-
mone co-secreted with both insulin and C-peptide from beta
cells. Patients with T1D are also deficient in IAPP. Amylin has
been implicated in bone physiology. In fact, genetic ablation
of amylin leads to bone loss in mice [27] and treatment with
amylin can in part reverse bone loss in ovariectomized rats
[28]. Analysis of amylin gene supports an evolutionary rela-
tionship to calcitonin [29]. In addition, a positive association
between amylin levels and BMD in women with anorexia
nervosa has been reported [30]. Thus, a number of investiga-
tions suggest a role for the pancreatic hormones on bone
metabolism.
A potential explanation of link between C-peptide and
LBMD may be the role of BMI conditioning the association.
In fact, hyperinsulinemia and insulin resistance are highly
correlated with BMI [31] and, in turn, they affect the bone.
As expected, in our investigation, we found a strong correla-
tion between BMI and C-peptide. To exclude any interference,
we corrected C-peptide for BMI but the results did not change.
Therefore, although BMI may be a confounding factor, there
is sufficient evidence to suggest that C-peptide may exert a
BMI-independent effect on bone mass, providing a further
link between nutrient intake and bone turnover. In this regard,
it has been showed that C-peptide predicted visceral fat accu-
mulation in both short-term and long-term follow-up [32];
thus, the hormonal changes may precede and predict the
BMI increase as suggested from other studies showing that
the secretion of bone-active hormones from the pancreas may
explain part of the relationship between fat mass and bone
mass [31]. However, further large-scale studies need to be
performed in order to clarify the role of the hormones secreted
by beta cells on bone metabolism especially in subjects not
affect by diabetes.
Of course, the link between C-peptide and BMD is still
neglected and needs to be studied in deep in experimental
study. In a recent investigation, using data from the NHAN
ES [16], a negative association between serum C-peptide and
BMD (expressed in g/cm2) was found independent of the
serum insulin levels. However, in the 40–59 years age group,
the group similar to our population, the authors showed that,
after additional data adjustment, the serum C-peptide levels
Table 5 Characteristics of the whole population according to C-peptide
concentration tertiles—ANOVA
Variables I tertile II tertile III tertile p value
C-peptide range (ng/ml) 0.80–1.36 1.40–2.02 2.03–3.80
Age (years) 54±7 53±5 52±5 0.69
BMI (kg/m2) 25.7±5 22.9±3 26.4±5 0.02
LBMD T-score −1.28±1 −1.10±1 −0.43±1 0.03
0.02a
LBMD Z-score −0.25±1 −0.14±1 0.51±1 0.04
FBMD T-score −1.15±1 −1.30±1 −0.95±1 0.50
FBMD Z-score −0.27±0.9 −0.42±1 −0.06±1 0.43
Calcium (mg/dL) 9.4±0.3 9.4±0.4 9.3±0.4 0.78
Phosphorus (mg/dL) 3.6±0.4 3.5±0.5 3.7±0.3 0.35
Glucose (mg/dL) 88.2±8 89.1±9 96.3±9 0.003
Insulin (μU/mL) 6.5±3 7.1±2 11.9±4 <0.001
C-peptide (ng/mL) 1.3±0.4 1.6±0.3 2.5±0.5 <0.001
HbA1c (%) 5.6±0.2 5.6±0.3 5.7±0.3 0.69
PTH (pg/mL) 47.6±18 45.8±21 42.1±18 0.54
25OH vit D (ng/mL) 25.1±11 25.9±9 27.9±11 0.59
NTx (nM BCE/nM
creatinine)
25.8±8 27.5±6 28.9±7 0.37
FGF-23 (pg/mL) 10.6±8 8.1±4 9.3±5 0.35
a LBMD: T-score, glucose, and BMI adjusted in the GLM
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were not associated with the spinal BMD [16]. In that study,
there was a lack of information about the measurement of
serum C-peptide [16]. Our study differs from that investiga-
tion in several points: We studied specifically postmenopausal
women without diabetes and in a definite age range; we re-
ported plasma glucose concentration of the whole population
(that was in normal range); we defined low BMD according to
the T-score and Z-score; whole-body DXA scan was not per-
formed in our study; we assessed C-peptide with a definite
methods. Finally, we investigated the effects of the interaction
with other factors on BMD like PTH, 25-OHvitamin D, and
FGF-23. Our findings are in agreement with a previous inves-
tigation [15] showing a positive correlation between both
LBMD and FBMD and C-peptide levels in patients with
Fig. 1 Scatter plot with the
individual data of the correlation
between LBMD and C-peptide
Fig. 2 The area under the ROC
curve for C-peptide to predict the
lumbar osteoporosis
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T1D. C-peptide, insulin, and amylin seem to be associated with
BMD in the same manner. C-peptide is commonly used in clin-
ical practice in preference to insulin assessment [10–12]. Thus, in
the future, C-peptide may be also measured to predict lumbar
osteoporosis, if its role will be confirmed. In our population, we
found a positive correlation between C-peptide andNTx (r=0.22
and p=0.05, data not showed) while a negative correlation was
expected. However, this finding is plausible since we showed
that postmenopausal women of the I tertile (those with the lower
C-peptide concentration and in which a greater NTx was expect-
ed) exercise habitually more than those of all other groups
(Table 3). In this regard, several studies reported that both the
walking exercise and a high-impact exercise training decreased
NTx levels in postmenopausal osteopenicwomen [33, 34]. Phys-
ical exercise appears to suppress bone turnover; thus, it is plau-
sible that in our investigation, women in the I tertile had also
lower NTx concentration (Table 2; I vs III tertile, p=0.009, in
the post hoc analysis), affecting the correlation between C-
peptide and NTx.
This study has several limitations that must be addressed.
The study could not determine causality. Furthermore, our
study was limited by its small size and cross-sectional design.
However, the statistical analysis is robust and adequate. The
clinical significance of the low C-peptide in osteoporosis
could be well deduced from the present results. The investi-
gation was done on representative samples of the Italian pop-
ulation; in fact, the study was conducted across two institu-
tions, potentially increasing the generalizability of our find-
ings from a geographical perspective. Our results were not
purely random as established by previous investigations [13,
26] and further confirmed by multiple analyses (as showed by
the statistical power and by the absence of collinearity and
interaction between variables, see the “Results” section). Of
course, this study may serve to generate hypotheses and
documenting this observation in “in vitro” research in the
future may be of great interest.
Unfortunately, we did not assess any marker of bone for-
mation but one of resorption alone as NTx. However, this is in
line with other investigations [35, 36].
Further studies are warranted to investigate the poten-
tial relationship between C-peptide and bone loss in
other population and to confirm that C-peptide could
become a helpful clinical tool in the assessment of
osteoporosis.
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